

In the Claims:

94 1. (Amended) A modified anti-viral peptide comprising:
a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545, and that exhibits anti-viral activity against human immunodeficiency virus (HIV), and a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

Please CANCEL claim 2. ✓

95 3. (Amended) The modified peptide of claim 1 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

4. (Amended) The modified peptide of claim 1 wherein said peptide is DP 107 and comprises the amino acid sequence of SEQ ID NO:2.

Please CANCEL claim 5. ✓

96 6. (Amended) The modified peptide of claim 1 wherein said peptide is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545.

Please CANCEL claims 7-18. ✓

19. (Amended) A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising a peptide wherein said peptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545, and that exhibits anti-viral activity against human immunodeficiency virus (HIV), modified with a succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

97 20. (Amended) The composition of claim 19 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

21. (Amended) The composition of claim 20 wherein said peptide is DP 107 comprising the amino acid sequence of SEQ ID NO:2.

Please CANCEL claims 22-30.

Please ADD the following NEW claims:

98 -- 31. (New) The composition of claim 19 wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545.

NRE 32. (New) A conjugated peptide comprising the modified anti-viral peptide of claim 1 covalently bonded to a blood component.

NRE 33. (New) The conjugated peptide of claim 32 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

NRE 34. (New) The conjugated peptide of claim 32, wherein said modified anti-viral peptide comprises the amino acid sequence of SEQ ID NO:2.

NRE 35. (New) The conjugated peptide of claim 32, wherein said modified anti-viral peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545.

AS 36. (New) A composition comprising the modified anti-viral peptide of claim 1.

37. (New) The composition of claim 36 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

38. (New) The composition of claim 36 wherein said modified anti-viral peptide comprises the amino acid sequence of SEQ ID NO:2.

39. (New) The composition of claim 36 wherein said modified anti-viral peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ

ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545.

NB 40. (New) A composition comprising the conjugated peptide of claim 31.

NB 41. (New) The composition of claim 40 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

NB 42. (New) The composition of claim 40 wherein said modified anti-viral peptide comprises the amino acid sequence of SEQ ID NO:2.

NB 43. (New) The composition of claim 40 wherein said modified anti-viral peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545.

Q8 *NO* 44. (New) A method of treating human immunodeficiency virus (HIV) infection in a patient, comprising administering to said patient an effective amount of the modified anti-viral peptide of claim 1.

NO 45. (New) The method of claim 44 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

NO 46. (New) The method of claim 44 wherein said modified anti-viral peptide comprises the amino acid sequence of SEQ ID NO:2.

47. (New) The method of claim 44 wherein said modified anti-viral peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545.

48. (New) A method of treating human immunodeficiency virus (HIV) infection in a patient, comprising:
reacting the modified anti-viral peptide of claim 1 for a time and under conditions effective to form a covalent bond between said modified anti-viral peptide and said blood component, thereby forming a conjugate; and
administering said conjugate to said patient.

98 49. (New) The method of claim 48 wherein said succinimidyl or maleimide containing group is a maleimido containing group which is reactive with a thiol group on a blood protein.

50. (New) The method of claim 48 wherein said modified anti-viral peptide comprises the amino acid sequence of SEQ ID NO:2.

51. (New) The method of claim 48 wherein said modified anti-viral peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, and SEQ ID NO:544, and SEQ ID NO:545. --